

# Canada's Health Tech Boom: AI, Telehealth, and Pharma Market Shifts Unveiled

Health Tech · Practice Test · 12 Questions

---

**1. In 2024, what was the projected revenue for the Canadian telehealth market, and what is its expected Compound Annual Growth Rate (CAGR) through 2030?**

- A) USD 13,514.2 million with a CAGR of 21.3%
- B) USD 3,057.68 billion with a CAGR of 21.83%
- C) USD 4,878.1 million with a CAGR of 19.6%
- D) USD 146.2 billion with a CAGR of 21.63%

**2. According to Pender Ventures' 2025 report, what was the approximate total venture funding for Canadian health tech in 2024, and what was the percentage decrease compared to 2023?**

- A) \$1.3 billion, a 10% decrease
- B) \$700 million, an 18% decrease
- C) \$1.57 billion, a 5% increase
- D) \$894 million, a 15% decrease

**3. What percentage of Canada's pharmaceutical sales represented the global market in 2024, and what was the estimated total expenditure on drugs in Canada for the same year?**

- A) 1.5% of global sales; \$40.58 billion expenditure
- B) 2.2% of global sales; \$43.7 billion expenditure
- C) 3.0% of global sales; \$51.56 billion expenditure
- D) 1.8% of global sales; \$32.88 billion expenditure

**4. In 2024, what was the revenue generated by the Canada healthcare analytics market, and what is its projected CAGR from 2025 to 2033?**

- A) USD 2,776.6 million with a CAGR of 16.2%
- B) USD 7,416.0 million with a CAGR of 14.6%
- C) USD 163.80 million with a CAGR of 36.81%
- D) USD 10.06 billion with a CAGR of 5.5%

**5. As of December 2025, what was the total VC investment in Canadian life sciences companies for 2024, and what percentage of this funding went to the Drug Discovery sector?**

- A) \$1.38 billion total investment; 12% to Drug Discovery
- B) \$1.57 billion total investment; 10% to Drug Discovery
- C) \$700 million total investment; 28% to Drug Discovery
- D) \$847 million total investment; 33% to Drug Discovery

**6. What proportion of Canadians possess at least one wearable device, and what is the projected market value of Canada's digital health market by 2033?**

- A) 30% of Canadians; USD 19.5 billion by 2033
- B) 40% of Canadians; USD 106.5 billion by 2033
- C) 50% of Canadians; USD 42.1 billion by 2033
- D) 25% of Canadians; USD 17.0 billion by 2033

**7. In 2024, what was the estimated value of Canada's medical devices market (excluding in vitro diagnostics), and what percentage did it represent of the global market?**

- A) USD 10.06 billion, 2.5% of global market
- B) USD 555.7 billion, 10% of global market
- C) USD 9.47 billion, 2.3% of global market
- D) USD 6.6 billion, 1.5% of global market

**8. What percentage of Canada's medical device exports were destined for the United States in 2024?**

- A) 50%
- B) 73%
- C) 65%
- D) 80%

**9. In the fiscal year 2024-2025, how many new drug shortage reports were submitted in Canada, and what was the total number of active (un-resolved or anticipated) drug shortages at the end of that period?**

- A) 2,588 new reports; 1,772 active shortages
- B) 1,439 new reports; 69 active shortages
- C) 69 new reports; 51 active shortages
- D) 59 new reports; 421 active shortages

**10. What was the total investment committed by DIGITAL (Canada's Global Innovation Cluster for Digital Technologies) in health projects by the end of the 2024/25 fiscal year, and what was the total investment from DIGITAL and its partners combined?**

- A) \$182 million in health projects; \$783 million total
- B) \$432 million in health projects; \$1.6 billion total
- C) \$324 million in health projects; \$783 million total
- D) \$324 million in health projects; \$1.6 billion total

**11. As of early 2025, approximately how many healthcare professionals in Canada had electronic access to comprehensive patient information through provincial and territorial systems?**

- A) Over 150,000
- B) Over 310,000
- C) Over 500,000
- D) Over 10,000

**12. In 2024, which segment led the Canadian pharmaceutical market by revenue, and what was its approximate market share?**

- A) Conventional drugs (small molecules); 54.7%
- B) Prescription drugs; not specified
- C) Cancer treatments; 18.1%
- D) Hospitals; not specified